secwatch.observer — SEC 8-K summary
======================================

Issuer:     BECTON DICKINSON & CO (BDX)
CIK:        0000010795
Form:       8-K
Filed at:   2025-07-14T23:59:59+00:00
Accession:  0001193125-25-158404
Event type: m_and_a
Sentiment:  positive
Materiality: 0.95
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BD to combine its Biosciences & Diagnostic Solutions with Waters in ~$17.5B RMT transaction
--------------------------------------------------------------------------------

- Transaction valued at ~$17.5B; BD shareholders to own ~39.2% of combined company; Waters ~60.8%.
- Pro forma 2025E revenue ~$6.5B, adjusted EBITDA ~$2.0B; mid-to-high single-digit revenue growth expected.
- Anticipated ~$345M annualized EBITDA synergies by 2030: ~$200M cost synergies by year 3, ~$290M revenue synergies by year 5.
- BD to receive ~$4B cash distribution pre-close; at least half allocated to share repurchases, remainder for debt repayment.
- Expected close around end of Q1 2026; subject to regulatory approvals and Waters shareholder approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/10795/000119312525158404/0001193125-25-158404-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/10795/000119312525158404/d41030d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-158404

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer